How is ceftobiprole used in Canada: the CLEAR study final results-Reference-Cited by-同舟云学术

How is ceftobiprole used in Canada: the CLEAR study final results

Published:2024-07-15 Issue: Volume: Page:1-8
ISSN:1478-7210
Container-title:Expert Review of Anti-infective Therapy
language:en
Short-container-title:Expert Review of Anti-infective Therapy

Author:

Zhanel George G.¹,Kosar Justin²,Baxter Melanie¹,Dhami Rita³,Borgia Sergio⁴,Irfan Neal⁵,Dow Gordon⁶,Dube Maxime⁷,von den Baumen Teagen Rolf³,Tascini Carlo⁸,Lee Anna⁹^ORCID,Chagla Zain¹⁰,Girouard Gabriel¹¹,Bourassa-Blanchette Samuel¹²^ORCID,Wu May¹³,Keynan Yoav¹,Walkty Andrew¹,Karlowsky James A.¹

Affiliation:

1. Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada

2. Department of Pharmacy, Royal University Hospital, Saskatoon, Saskatchewan, Canada

3. Department of Pharmacy, London Health Sciences Centre, London, Ontario, Canada

4. Section of Infectious Diseases, William Osler Health System, Brampton, Ontario, Canada

5. Department of Pharmacy, Hamilton Health Sciences Centre, Hamilton, Ontario, Canada

6. Section of Infectious Diseases, Department of Medicine, The Moncton Hospital, New Brunswick, Canada

7. Department of Pharmacy, Sainte-Croix Hospital, Drummondville, Québec, Canada

8. Infectious Diseases Clinic, DAME, Udine University Hospital, Udine, Italy

9. Department of Pharmacy, Scarborough Health Network, Toronto, Ontario, Canada

10. Section of Infectious Diseases, St. Joseph’s Healthcare, Hamilton, Ontario, Canada

11. Section of Infectious Diseases, Dr. Georges-L.-Dumont University Hospital, Moncton, New Brunswich, Canada

12. Medical Microbiology and Infectious Diseases, Memorial University of Newfoundland Faculty of Medicine, St. John’s, Newfoundland, Canada

13. Department of Pharmacy, Surrey Memorial Hospital, Vancouver, British Columbia, Canada

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/14787210.2024.2374280

Reference44 articles.

1. Ceftobiprole

2. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model

3. Monte Carlo simulation analysis of ceftobiprole, dalbavancin, daptomycin, tigecycline, linezolid and vancomycin pharmacodynamics against intensive care unit-isolated methicillin-resistantStaphylococcus aureus

4. A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation

5. A Phase 3 Randomized Double-Blind Comparison of Ceftobiprole Medocaril Versus Ceftazidime Plus Linezolid for the Treatment of Hospital-Acquired Pneumonia